Molecular Docking Investigation of Dioscorea alata Compounds Binding to CCKBR, CHRM3, CHRM5, and H2R for Gastric Ulcer Treatment
DOI:
https://doi.org/10.48048/tis.2024.7358Keywords:
CCKBR, CHRM3, CHRM, Dioscorea alata, Gastric ulcer, H2RAbstract
Gastric ulcer is a pathological condition characterized by damage to the mucosal and submucosal tissue layers of the stomach. The main proteins targeted in the treatment of gastric ulcers are CCKBR, CHRM3, CHRM5, and H2R because of their roles in the regulation of gastric acid secretion. Dioscorea alata (DA) is known to contain various active compounds with high sapogenin, diosgenin, and dioscorin content, in addition to its carbohydrate content. We investigated the potential of DA compounds to bind to these proteins in silico. Compound and protein structures were retrieved from PubChem (https://pubchem.ncbi.nlm.nih.gov), ChemSpider (http://www.chemspider.com), and the RCSB PDB (https://rcsb.org). Proteins and compounds are prepared first, and then docked to obtain the interactions that might form, and finally visualized to observe the interactions that have been constructed. The results showed that diosgenin and prosapogenin have potential as inhibitors of CCKBR and CHRM5, and diosgenin and dimethyl batatasin IV have potential as inhibitors of CHRM3 and H2R. We conclude that diosgenin, prosapogenin, and dimethyl batatasin IV in DA compounds have the potential to inhibit CCKBR, CHRM3, CHRM5, and H2R for gastric ulcer treatment. It is necessary to further study the effect of Dioscorea alata in vitro through a gastric ulcer model study.
HIGHLIGHTS
- Dioscorea alata (DA) is known to contain various active compounds with high sapogenin, diosgenin, and dioscorin content in addition to its carbohydrate content
- Gastritis (gastric ulcer) is a pathological condition characterized by damage to the mucosal and sub-mucosal tissue layers of the stomach. The main proteins targeted in the treatment of gastric ulcers are CCKBR, CHRM3, CHRM5, and H2R because of their roles in the regulation of gastric acid secretion
- We performed an in-silico study to investigate the potential of DA compounds to inhibit these proteins. Compound and protein structures were retrieved from PubChem, ChemSpider, and the RCSB PDB. Proteins were prepared with Swiss PDB viewer v. 4.10. Compounds were prepared with Open Babel in Cytoscape v.3.9.1. Docking was done with AutoDock Vina in PyRx v.0.9.7. Visualization was done with Discovery Studio v. 19.1
- We determined that several DA compounds have the potential to act as inhibitors of CCKBR, CHRM3, CHRM5, and H2R by reviewing the predicted binding energy, competitive properties based on literature studies and the bioactivity and molecular docking analysis. The results of this study are expected to be the basis for further gastric ulcer treatment research
GRAPHICAL ABSTRACT
Downloads
Metrics
References
MT Umasugi, FF Soulissa, I Susanti and GR Latuperissa. The effect of health education on gastritis prevention behavior among high school students. Jurnal Ners 2020; 15, 20515.
J Phan, JN Benhammou and JR Pisegna. Gastric hypersecretory states: Investigation and management. Curr. Treat. Options Gastroenterol. 2015; 13, 386-97.
PA Ruiz-Hurtado, L Garduño-Siciliano, P Domínguez-Verano, D Balderas-Cordero, G Gorgua-Jiménez, O Canales-Álvarez, MM Canales-Martínez and MA Rodríguez-Monroy. Propolis and its gastroprotective effects on NSAID-induced gastric ulcer disease: A systematic review. Nutrients 2021; 13, 3169.
L Kuna, J Jakab, R Smolic, N Raguz-Lucic, A Vcev and M Smolic. Peptic ulcer disease: A brief review of conventional therapy and herbal treatment options. J. Clin. Med. 2019; 8, 179.
AS Tijani, MJ Temitayo and OE Farombi. Cytoprotective effect of methanol extract of laportea aestuans on acidified ethanol-induced gastric ulcer in male wistar rats. Trends Sci. 2022; 19, 4648.
R Deshmukh, RK Harwansh, M Prajapati and B Sharma. Formulation and evaluation of oral mucoadhesive microspheres of ofloxacin for peptic ulcer use. Trends Sci. 2023; 20, 5751.
JE Obidiegwu, JB Lyons and CA Chilaka. The dioscorea genus (Yam): An appraisal of nutritional and therapeutic potentials. Foods 2020; 9, 1304.
H Noda, J Yamashita, S Fuse, R Pooma, M Poopath, H Tobe and MN Tamura. A large-scale phylogenetic analysis of dioscorea (Dioscoreaceae), with reference to character evolution and subgeneric recognition. Acta Phytotaxonomica Geobotanica 2020; 71, 103-28.
SNN Makiyah, M Kita, I Setyawati and S Tasminatun. Dioscorea alata L. tubers improve diabetes through Anti-hyperglycemia. Indonesian Biomed. J. 2022; 14, 365-75.
RA Laskowski, J Jabłońska, L Pravda, RS Vařeková and JM Thornton. PDBsum: Structural summaries of PDB entries. Protein Sci. 2018; 27, 129-34.
DA Filimonov, AA Lagunin, TA Gloriozova, AV Rudik, DS Druzhilovskii, PV Pogodin and VV Poroikov. Prediction of the biological activity spectra of organic compounds using the pass online web resource. Chem. Heterocycl. Comp. 2014; 50, 444-57.
S Dacha, M Razvi, J Massaad, Q Cai and M Wehbi. Hypergastrinemia. Gastroenterol. Rep. 2015; 3, 201-8.
C Locci, L Cuzzolin, G Cheri, L Saderi, G Sotgiu and R Antonucci. Clinical use of gastric antisecretory drugs in hospitalized pediatric patients. J. Clin. Med. 2023; 12, 368.
V Suresh, K Byers, UC Rajesh, F Caiazza, G Zhu, CS Craik, K Kirkwood, VJ Davisson and DA Sheik. Translation of a protease turnover assay for clinical discrimination of mucinous pancreatic cysts. Diagnostics 2022; 12, 1343.
G Bindea, B Mlecnik, H Hackl, P Charoentong, M Tosolini, A Kirilovsky, F Wolf-Herman, F Pagès, Z Trajanoski and J Galon. ClueGO: A cytoscape plug-in to decipher functionally grouped gene ontology and pathway annotation networks. Bioinformatics 2009; 25, 1091-3.
P Shannon, A Markiel, O Ozier, NS Baliga, JT Wang, D Ramage, N Amin, B Schwikowski and T Ideker. Cytoscape: A software environment for integrated models of biomolecular interaction networks. Genome Res. 2003; 13, 2498-504.
D Szklarczyk, AL Gable, D Lyon, A Junge, S Wyder, J Huerta-Cepas, M Simonovic, NT Doncheva, JH Morris, P Bork, LJ Jensen and CV Mering. STRING v11: Protein-protein association networks with increased coverage, supporting functional discovery in genome-wide experimental datasets. Nucleic Acids Res. 2019; 47, D607-D613.
TGO Consortium. The gene ontology in 2010: Extensions and refinements. Nucleic Acids Res. 2010; 38, D331- D335.
M Kanehisa, M Furumichi, Y Sato, M Kawashima and M Ishiguro-Watanabe. KEGG for taxonomy-based analysis of pathways and genomes. Nucleic Acids Res. 2022; 51, D587-D592.
S Dallakyan and AJ Olson. Small-molecule library screening by docking with PyRx. Meth. Mol. Biol. 2015; 1263, 243-50.
NM O’Boyle, M Banck, CA James, C Morley, T Vandermeersch and GR Hutchison. Open babel: An open chemical toolbox. J. Cheminformatics 2011; 3, 33.
O Trott and AJ Olson. AutoDock vina: Improving the speed and accuracy of docking with a new scoring function, efficient optimization and multithreading. J. Comput. Chem. 2010; 31, 455-61.
TS Thorsen, R Matt, WI Weis and B Kobilka. Modified T4 lysozyme fusion proteins facilitate G Protein-coupled receptor crystallogenesis. Structure 2014; 22, 1657-64.
Z Vuckovic, PR Gentry, AE Berizzi, K Hirata, S Varghese, G Thompson, ETVD Westhuizen, WAC Burger, R Rahmani, C Valant, CJ Langmead, CW Lindsley, JB Baell, AB Tobin, PM Sexton, A Christopoulos and DM Thal. Crystal structure of the M5 muscarinic acetylcholine receptor. Proc. Natl. Acad. Sci. Unit. States Am. 2019; 116, 26001-7.
X Zhang, C He, M Wang, Q Zhou, D Yang, Y Zhu, W Feng, H Zhang, A Dai, X Chu, J Wang, Z Yang, Y Jiang, U Sensfuss, Q Tan, S Han, S Reedtz-Runge, XH Eric, S Zhao, W Ming-Wei, B Wu and Q Zhao. Structures of the human cholecystokinin receptors bound to agonists and antagonists. Nat. Chem. Biol. 2021; 17, 1230-7.
MJ Robertson, MM Papasergi-Scott, F He, AB Seven, JG Meyerowitz, O Panova, MC Peroto, T Che and G Skiniotis. Structure determination of inactive-state GPCRs with a universal nanobody. Nat. Struct. Mol. Biol. 2022; 29, 1188-95.
J Yu-Pu and L Pi-Hui. Biological and pharmacological effects of synthetic saponins. Molecules 2020; 25, 4974.
M Jesus, APJ Martins, E Gallardo and S Silvestre. Diosgenin: Recent highlights on pharmacology and analytical methodology. J. Anal. Meth. Chem. 2016; 2016, 4156293.
J Da-Hye, P Hye-Jin, B Hye-Eun, P Yoon-Moon, K Tae-Wan, K Byung-Oh, U Sung-Hee and S Pyo. Diosgenin inhibits macrophage-derived inflammatory mediators through downregulation of CK2, JNK, NF-kappaB and AP-1 activation. Int. Immunopharm. 2010; 10, 1047-54.
B Salehi, B Sener, M Kilic, J Sharifi-Rad, R Naz, Z Yousaf, FN Mudau, PVT Fokou, SM Ezzat, MHE Bishbishy, Y Taheri, G Lucariello, A Durazzo, M Lucarini, HAR Suleria and A Santini. Dioscorea plants: A genus rich in vital nutrapharmaceuticals-a review. Iranian J. Pharmaceut. Res. 2019; 18, 68-89.
W Tian-Xiao, Z Zhong-Qing, Y Cong, S Xiao-Yan, L Ying-Hua and Z Fang-Li. Prosapogenin A induces apoptosis in human cancer cells in vitro via inhibition of the STAT3 signaling pathway and glycolysis. Oncol. Lett. 2019; 6, 1323-8.
H Xie, L Zhang, S Jing, J Zhou, Q Wu, Y Yang, Y Chen, C Yang, G Xia, Y Shen and H Yang. Efficient enzymatic hydrolysis of protogracillin for clean preparation of prosapogenin a by response surface methodology optimization. Green Chem. Lett. Rev. 2022; 15, 837-46.
AT Mbaveng, GF Chi, GS Nguenang, S Abdelfatah, RVT Sop, BT Ngadjui, V Kuete and T Efferth. Cytotoxicity of a naturally occuring spirostanol saponin, progenin III, towards a broad range of cancer cell lines by induction of apoptosis, autophagy and necroptosis. Chem. Biol. Interact. 2020; 326, 109141.
T Hashimoto, K Hasegawa and A Kawarada. Batatasins: New dormancy-inducing substances of yam bulbils. Planta 1972; 108, 369-74.
S Ghosh. Phytochemsitry and therapeutic potential of medicinal plant: Dioscorea bulbifera. Med. Chem. 2015; 5, 160.
J Zhu, W Hu, D Wu, L Chen and X Liu. Investigation of the interaction of batatasin derivatives with human serum albumin using voltammetric and spectroscopic methods. RSC Adv. 2016; 6, 36281-92.
A Grigorian, MYC Lin and CD Virgilio. Severe epigastric pain with nausea and vomiting. In: CD Virgilio and A Grigorian (Eds.). Surgery. Springer Cham, Switzerland.
X Xie, K Ren, Z Zhou, C Dang and H Zhang. The global, regional and national burden of peptic ulcer disease from 1990 to 2019: A population-based study. BMC Gastroenterol. 2022; 22, 58.
AC Kruse, BK Kobilka, D Gautam, PM Sexton, A Christopoulos and J Wess. Muscarinic acetylcholine receptors: Novel opportunities for drug development. Nat. Rev. Drug Discov. 2014; 13, 549-60.
HD Langtry, SM Grant and KL Goa. Famotidine. An updated review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in peptic ulcer disease and other allied diseases. Drugs 1989; 38, 551-90.
RBH Ii, RBH Iii, T Cannon, M Rappai, J Studdard, D Paul and TP Dooley. Dual-histamine receptor blockade with cetirizine - famotidine reduces pulmonary symptoms in covid-19 patients. Pulm. Pharmacol. Therapeut. 2020; 63, 101942.
PJ Barnes, MG Belvisi, JC Mak, EB Haddad and B O’Connor. Tiotropium bromide (Ba 679 BR), a novel long-acting muscarinic antagonist for the treatment of obstructive airways disease. Life Sci. 1995; 56, 853-9.
T Matsuyama, K Machida, Y Motomura, K Takagi, Y Doutake, A Tanoue-Hamu, K Kondo, K Mizuno, K Moro and H Inoue. Long-acting muscarinic antagonist regulates group 2 innate lymphoid cell-dependent airway eosinophilic inflammation. Allergy 2021; 76, 2785-96.
D Johnston and K Jepson. Use of pentagastrin in a test of gastric acid secretion. Lancet 1967; 290, 585-8.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2023 Walailak University
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
